Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure

Alfonso Quintas-Cardama, Hagop Kantarjian, Dan Jones, Claude Nicaise, Susan O'Brien, Francis Giles, Moshe Talpaz, Jorge Cortes

Research output: Contribution to journalArticle

Abstract

Developing strategies to counteract imatinib resistance constitutes a challenge in chronic myelogenous leukemia (CML). Therapy with the tyrosine kinase inhibitors nilotinib (AMN107) and dasatinib (BMS-354825) has produced high rates of hematologic and cytogenetic response. Src kinase activation has been linked to Bcr-Abl-mediated leukemogenesis and CML progression. In addition to binding Abl kinase with less stringent conformational requirements than imatinib, dasatinib is a potent Src kinase inhibitor. In the current study, we report on 23 patients with CML (19 of them in accelerated or blastic phases) treated with dasatinib after treatment failure with both imatinib and nilotinib. More than half (13; 57%) of 23 patients responded to dasatinib: 10 (43%) had a complete hematologic response (CHR), including 7 (30%) who had a cytogenetic response (2 complete, 4 partial, and 1 minor). These results suggest that dasatinib may be active in some patients after failure with both imatinib and nilotinib.

Original languageEnglish (US)
Pages (from-to)497-499
Number of pages3
JournalBlood
Volume109
Issue number2
DOIs
StatePublished - Jan 15 2007
Externally publishedYes

Fingerprint

Philadelphia Chromosome
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chromosomes
src-Family Kinases
Cytogenetics
Therapeutics
Treatment Failure
Protein-Tyrosine Kinases
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide
Imatinib Mesylate
Dasatinib
Phosphotransferases
Chemical activation

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. / Quintas-Cardama, Alfonso; Kantarjian, Hagop; Jones, Dan; Nicaise, Claude; O'Brien, Susan; Giles, Francis; Talpaz, Moshe; Cortes, Jorge.

In: Blood, Vol. 109, No. 2, 15.01.2007, p. 497-499.

Research output: Contribution to journalArticle

Quintas-Cardama, Alfonso ; Kantarjian, Hagop ; Jones, Dan ; Nicaise, Claude ; O'Brien, Susan ; Giles, Francis ; Talpaz, Moshe ; Cortes, Jorge. / Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. In: Blood. 2007 ; Vol. 109, No. 2. pp. 497-499.
@article{49b77974cfdf464fa4e584cd09103415,
title = "Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure",
abstract = "Developing strategies to counteract imatinib resistance constitutes a challenge in chronic myelogenous leukemia (CML). Therapy with the tyrosine kinase inhibitors nilotinib (AMN107) and dasatinib (BMS-354825) has produced high rates of hematologic and cytogenetic response. Src kinase activation has been linked to Bcr-Abl-mediated leukemogenesis and CML progression. In addition to binding Abl kinase with less stringent conformational requirements than imatinib, dasatinib is a potent Src kinase inhibitor. In the current study, we report on 23 patients with CML (19 of them in accelerated or blastic phases) treated with dasatinib after treatment failure with both imatinib and nilotinib. More than half (13; 57{\%}) of 23 patients responded to dasatinib: 10 (43{\%}) had a complete hematologic response (CHR), including 7 (30{\%}) who had a cytogenetic response (2 complete, 4 partial, and 1 minor). These results suggest that dasatinib may be active in some patients after failure with both imatinib and nilotinib.",
author = "Alfonso Quintas-Cardama and Hagop Kantarjian and Dan Jones and Claude Nicaise and Susan O'Brien and Francis Giles and Moshe Talpaz and Jorge Cortes",
year = "2007",
month = "1",
day = "15",
doi = "10.1182/blood-2006-07-035493",
language = "English (US)",
volume = "109",
pages = "497--499",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "2",

}

TY - JOUR

T1 - Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure

AU - Quintas-Cardama, Alfonso

AU - Kantarjian, Hagop

AU - Jones, Dan

AU - Nicaise, Claude

AU - O'Brien, Susan

AU - Giles, Francis

AU - Talpaz, Moshe

AU - Cortes, Jorge

PY - 2007/1/15

Y1 - 2007/1/15

N2 - Developing strategies to counteract imatinib resistance constitutes a challenge in chronic myelogenous leukemia (CML). Therapy with the tyrosine kinase inhibitors nilotinib (AMN107) and dasatinib (BMS-354825) has produced high rates of hematologic and cytogenetic response. Src kinase activation has been linked to Bcr-Abl-mediated leukemogenesis and CML progression. In addition to binding Abl kinase with less stringent conformational requirements than imatinib, dasatinib is a potent Src kinase inhibitor. In the current study, we report on 23 patients with CML (19 of them in accelerated or blastic phases) treated with dasatinib after treatment failure with both imatinib and nilotinib. More than half (13; 57%) of 23 patients responded to dasatinib: 10 (43%) had a complete hematologic response (CHR), including 7 (30%) who had a cytogenetic response (2 complete, 4 partial, and 1 minor). These results suggest that dasatinib may be active in some patients after failure with both imatinib and nilotinib.

AB - Developing strategies to counteract imatinib resistance constitutes a challenge in chronic myelogenous leukemia (CML). Therapy with the tyrosine kinase inhibitors nilotinib (AMN107) and dasatinib (BMS-354825) has produced high rates of hematologic and cytogenetic response. Src kinase activation has been linked to Bcr-Abl-mediated leukemogenesis and CML progression. In addition to binding Abl kinase with less stringent conformational requirements than imatinib, dasatinib is a potent Src kinase inhibitor. In the current study, we report on 23 patients with CML (19 of them in accelerated or blastic phases) treated with dasatinib after treatment failure with both imatinib and nilotinib. More than half (13; 57%) of 23 patients responded to dasatinib: 10 (43%) had a complete hematologic response (CHR), including 7 (30%) who had a cytogenetic response (2 complete, 4 partial, and 1 minor). These results suggest that dasatinib may be active in some patients after failure with both imatinib and nilotinib.

UR - http://www.scopus.com/inward/record.url?scp=33846200681&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846200681&partnerID=8YFLogxK

U2 - 10.1182/blood-2006-07-035493

DO - 10.1182/blood-2006-07-035493

M3 - Article

C2 - 16990591

AN - SCOPUS:33846200681

VL - 109

SP - 497

EP - 499

JO - Blood

JF - Blood

SN - 0006-4971

IS - 2

ER -